Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 3/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.63 |
| ▸ | LMNA | P02545 | 7/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.63 |
| ▸ | MAPT | P10636 | 5/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 4/20 | 0.63 |
| ▸ | SHBG | P04278 | 4/20 | 0.63 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.63 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.63 |
| ▸ | PGR | P06401 | 3/20 | 0.63 |
| ▸ | AR | P10275 | 3/20 | 0.63 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.63 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.63 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.63 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.63 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.63 |
| ▸ | MEN1 | O00255 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14117501 | 1.00 | SRD5A2 (0.64) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4247713 | 0.90 | CYP3A4 (0.67) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4247715 | 0.90 | CYP3A4 (0.67) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4252611 | 0.90 | SRD5A2 (0.65) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4251319 | 0.89 | LMNA (0.68) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4251320 | 0.89 | LMNA (0.68) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4251328 | 0.88 | LMNA (0.67) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4251322 | 0.88 | LMNA (0.67) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4242664 | 0.88 | SRD5A2 (0.67) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL4242667 | 0.88 | SRD5A2 (0.67) | SRD5A2CYP3A4LMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1434786-A4 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | claimed |
| US-7402577-B2 | Androstane 17-beta-carboxamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-07-22 | — | — | US | claimed |
| US-20040220159-A1 | Androstane 17-beta-carboxamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | claimed |
| EP-1434786-A1 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-07-07 | — | — | EP | claimed |
| WO-2003029268-A1 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-10 | — | — | WO | claimed |
| EP-1434786-A4 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO INC (US) | 2009-03-25 | — | — | EP | disclosed |
| US-7402577-B2 | Androstane 17-beta-carboxamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20040220159-A1 | Androstane 17-beta-carboxamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2004-11-04 | — | — | US | disclosed |
| EP-1434786-A1 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2004-07-07 | — | — | EP | disclosed |
| WO-2003029268-A1 | ANDROSTANE 17-BETA-CARBOXAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2003-04-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220159-A1 | Androstane 17-beta-carboxamides as androgen receptor modulators | CYP19A1, SHBG, AR | SRD5A2 12/4885CYP3A4 828/4885LMNA 2539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.